Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

https://www.thailandmedical.news/news/breaking-covid-19-supplements-us-study-finds-that-resolvins-fr

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 195
Posts 16,222
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Gilead Sciences & Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop & Co-Commercialize Next-Gener... Business Wire - 7/13/2020 4:05:00 PM
Gilead: Remdesivir Associated With Recovery, Reduction in Mortality Risk Dow Jones News - 7/10/2020 9:27:00 AM
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19 Business Wire - 7/10/2020 8:30:00 AM
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders Business Wire - 7/8/2020 4:01:00 AM
Precision BioSciences Says Gilead Ends Hepatitis B Collaboration Dow Jones News - 7/6/2020 8:23:00 AM
Correction to Poor Performance of Health-Care Stocks Article Dow Jones News - 7/5/2020 6:43:00 PM
Coronavirus Is No Cure for Health-Care Stocks Dow Jones News - 7/5/2020 5:17:00 PM
Coronavirus Is No Cure for Health-Care Stocks Dow Jones News - 7/5/2020 8:29:00 AM
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults Business Wire - 7/4/2020 3:01:00 AM
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Len... Business Wire - 7/4/2020 3:01:00 AM
European Commission Authorizes Gilead's Marketing of Remdesivir for Covid-19 Treatment Dow Jones News - 7/3/2020 9:14:00 AM
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COV... Business Wire - 7/3/2020 7:56:00 AM
Arthritis Drug Fails in Study of Covid-19 Patients Dow Jones News - 7/2/2020 6:17:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:04:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 4:56:35 PM
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment & Cure Research Data P... Business Wire - 7/1/2020 8:30:00 AM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 7th Update Dow Jones News - 6/29/2020 5:23:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 6th Update Dow Jones News - 6/29/2020 4:37:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 5th Update Dow Jones News - 6/29/2020 4:24:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 4th Update Dow Jones News - 6/29/2020 4:14:00 PM
Correction to Cost of Covid-19 Drug Remdesivir Article Dow Jones News - 6/29/2020 1:34:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance Dow Jones News - 6/29/2020 7:29:00 AM
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences Business Wire - 6/29/2020 7:00:00 AM
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics Business Wire - 6/23/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/16/2020 6:52:28 PM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist